Australian biotech market watch 28/08/09
Friday, 28 August, 2009
Another week of gains on the All Ordinaries saw the index rise to 4,487, up over 4% for the week, with retailers leading the charge today.
The S&P/ASX 200 Health Care index also took a jump today, lifting over 1.5% to 8,474, after a dip earlier in the week.
At the head of the pack is Sonic Healthcare (ASX:SHL), up an impressive 8.5% to $13.88, after its profits beat even optimistic predictions.
Sirtex Medical (ASX:SRX) was not far behind, posting a healthy 72% increase in revenue for the financial year, aided not only by increased sales but also currency movements. Today it's up 7.7% to $4.64.
A healthy $20.8m profit for Blackmores (ASX:BKL) buoyed its share price by 3.7% to a shade under $20, it's best price for over a year.
Healthscope (ASX:HSP) also put in a strong showing, up 4% even to $4.68, after announcing a new capital raising.
Cellestis (ASX:CST), which posted a strong result earlier this week, nudged up 4.6% to $3.62.
CSL (ASX:CSL) has been in the news of late over the bumps in getting its swine flu vaccine out to the Australian public. It's price rose 22c to $32.50 in a day of light trading. ResMed (ASX:RMD) was steady, and the last of the Big Three, Cochlear (ASX:COH), saw an 81c drop to $57.88 on the back of a share issue earlier this week.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
